| __timestamp | Amphastar Pharmaceuticals, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 104381000 |
| Thursday, January 1, 2015 | 37065000 | 100171000 |
| Friday, January 1, 2016 | 41199000 | 102726000 |
| Sunday, January 1, 2017 | 43415000 | 96171000 |
| Monday, January 1, 2018 | 57564000 | 66449000 |
| Tuesday, January 1, 2019 | 68853000 | 42672000 |
| Wednesday, January 1, 2020 | 67229000 | 42534000 |
| Friday, January 1, 2021 | 60932000 | 53311000 |
| Saturday, January 1, 2022 | 74771000 | 82258000 |
| Sunday, January 1, 2023 | 73741000 | 118011000 |
Unleashing insights
In the ever-evolving world of pharmaceuticals, innovation is key to staying ahead. Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have shown distinct approaches to research and development (R&D) spending over the past decade. From 2014 to 2023, Celldex consistently outspent Amphastar, with an average R&D expenditure nearly 46% higher. Notably, in 2023, Celldex's R&D spending peaked at approximately 118 million, marking a 40% increase from 2022. In contrast, Amphastar's spending grew steadily, reaching around 74 million in 2023, a 30% rise from 2014. This trend highlights Celldex's aggressive investment in innovation, potentially positioning it as a leader in breakthrough therapies. Meanwhile, Amphastar's consistent growth reflects a more measured approach, balancing innovation with financial prudence. As the pharmaceutical landscape continues to shift, these spending patterns offer insights into each company's strategic priorities and potential future trajectories.
Research and Development: Comparing Key Metrics for Johnson & Johnson and Celldex Therapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: BeiGene, Ltd. vs Celldex Therapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Celldex Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Blueprint Medicines Corporation vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Grifols, S.A. and Celldex Therapeutics, Inc.
R&D Spending Showdown: Corcept Therapeutics Incorporated vs Celldex Therapeutics, Inc.
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.